7.65
-0.35 (-4.38%)
| Previous Close | 8.00 |
| Open | 8.03 |
| Volume | 81,347 |
| Avg. Volume (3M) | 55,162 |
| Market Cap | 335,105,184 |
| Price / Sales | 53.71 |
| Price / Book | 2.45 |
| 52 Weeks Range | |
| Earnings Date | 13 May 2025 |
| Operating Margin (TTM) | -1,449.80% |
| Diluted EPS (TTM) | -1.95 |
| Quarterly Revenue Growth (YOY) | -30.80% |
| Total Debt/Equity (MRQ) | 20.00% |
| Current Ratio (MRQ) | 4.56 |
| Operating Cash Flow (TTM) | -49.23 M |
| Levered Free Cash Flow (TTM) | -31.69 M |
| Return on Assets (TTM) | -26.02% |
| Return on Equity (TTM) | -56.08% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Mixed | Mixed |
| Medical Instruments & Supplies (Global) | Bearish | Mixed | |
| Stock | Nyxoah SA | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 0.38 |
|
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoah's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Small Core |
| % Held by Insiders | 38.32% |
| % Held by Institutions | 33.00% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Rossmore Private Capital | 30 Sep 2024 | 117,940 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 15.00 (HC Wainwright & Co., 96.08%) | Buy |
| 15.00 (Stifel, 96.08%) | Buy | |
| Median | 15.00 (96.08%) | |
| Average | 15.00 (96.08%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 9.71 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 26 Mar 2025 | 15.00 (96.08%) | Buy | 8.91 |
| Stifel | 14 Mar 2025 | 15.00 (96.08%) | Buy | 10.51 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |